secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000012208-24-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q2 net sales down 6.3% YoY; Life Science weak, Diagnostics up 2.1%; board adds $500M buyback
--------------------------------------------------------------------------------

- Q2 net sales $638.5M, -6.3% YoY; Life Science $250.5M (-16.5%), Diagnostics $387.9M (+2.1%).
- Gross margin improved to 55.6% from 53.2%; operating income $101.5M vs $89.6M YoY.
- Net loss $2,165.5M ($76.26 diluted EPS) mainly due to non-cash fair value adjustment of Sartorius investment.
- CEO expects more modest pace of market recovery than originally anticipated.
- Board authorized additional $500M share repurchase; total available ~$578M as of July 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000050/0000012208-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000050/bio-20240729.htm
  HTML page:      https://secwatch.observer/filing/0000012208-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer